Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.

Guselkumab (Tremfya) results in clinically meaningful improvements demonstrated across symptomatic and histo-endoscopic outcome measures for patients with ulcerative colitis compared with placebo, ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...